Background: The NLRP3-mediated pyroptosis is a key player in the development of the age-associated neurodegenerative disease. Zanthoxylum bungeanum Maxim (Rutaceae), a homologous of medicine and foodstuff, has previously been demonstrated the potential prevention of cognitive dysfunction in aging mice. However, it is still unknown which fraction is the material basis responsible for their therapeutic effects and whether Z. bungeanum could confer anti-cognitive deficits activity via restraining NLRP3-mediated pyroptosis. Thus, in the current study, we explored the active fraction of Z. bungeanum against cognitive deficits and its underlying mechanism.Methods: In the present study, the D-galactose-induced mouse model of aging was established to explore the effect of cognitive impairment of four fractions of Z. bungeanum, including petroleum ether (PE), methylene chloride (DCM), ethyl acetate (EA), and n-butanol (N-BAI). We next activated the NLRP3 inflammasome in BV-2 microglia cells to investigate the mechanisms for the neuroprotective effect of the active fraction of Z. bungeanum.Results: We demonstrated that the mice treated with EA had significantly alleviated the memory deficit induced by D-galactose. Meanwhile, EA up-regulated the cortex NeuN protein level, improved the survival and morphology of hippocampal neurons. We further found that EA significantly alleviated oxidative damage, inhibited activation of microglia, and suppressed NLRP3 inflammasome activation and subsequent cleaved Caspase-1, IL-1β, IL-18, and GSDMD-N. Correspondingly, in vitro data showed that EA protected BV-2 cells against Lipopolysaccharide (LPS) and adenosine triphosphate (ATP) elicited NLRP3 inflammasome activation and pyroptosis, evidenced by declined the protein levels of NLRP3, cleaved Caspase-1, IL-1β, IL-18, and GSDMD-N. These data indicated that EA inhibited NLRP3-mediated pyroptosis.Conclusions: Our work revealed that the EA active fraction of Z. bungeanum protected neurons from inflammation through inhibition of NLRP3 and subsequent pyroptosis in microglia, and suggested promising clinical use of EA for age-associated neurodegenerative disease.